´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷) : 2022-05-29±³À°ÀÏÀÚ : 2022-05-29
±³À°Àå¼Ò : ¼¿ï µå·¡°ï½ÃƼȣÅÚ
±³À°ÁÖÁ¦ :
KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
ksn@ksn.or.kr ±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 34 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í ¡áȸ¿ø: »çÀü(100,000)/ÇöÀå(150,000) ¡áºñȸ¿ø: »çÀü(150,000)/ ÇöÀå(200,000) ¡áFellow-in-training,Resident,Trainee,Student,Nurse,etc: »çÀü(50,000)/ ÇöÀå(35,000) *Medical Student: ¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-29 Room 1(5F) 08:30~09:00 Dialysis Adequacy Update (Hemo Dialysis /Peritoneal Dialysis Adequacy) Áø±Ôº¹(°è¸í´ëÇб³ µ¿»êº´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 09:00~09:30 Management of Secondary Hyperparathyroidism in Dialysis Patients: Case Oriented ÀÌÀ¯È£(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 09:30~10:00 30 Incremental, Hybrid, and Extended Dialysis ±æÈ¿¿í(õ¾È¼øõÇ⺴¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 10:00~10:30 Anemia Management in Dialysis Patients: Target Ferritin and Hemoglobin ±è¼¸°(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 10:40~11:10 Clinical Implications and Prescriptions of On-Line Hemodiafiltration ±èÁø¼÷(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-29 Room 1(5F) 11:10~11:40 Prescription of Automated Peritoneal Dialysis °°æÇ¥(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 05-29 Room 1(5F) 11:40~12:10 Evaluation and Management of Av Access as a Nephrologist ÀÌÇü¼®(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 12:10~12:40 Non-infectious Peritoneal Dialysis Complications ¹Ú°æ¼±(¿ï»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 13:30~14:10 ÄáÆϺ´ °øÅë µ¥ÀÌÅÍ ¸ðµ¨ ¿¬±¸È¸ °úÁ¦ ±¸È£¼®(ÀÎÁ¦¹éº´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 14:10~14:50 ½ÅÀåÀ̽ÄȯÀÚ¿¡¼ °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º ¿¹¹æ¿ä¹ýÀÇ È¿°úºÐ¼® ¿¬±¸ Á¤°æȯ(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-29 Room 1(5F) 14:50~15:30 Genetic identification of inherited cystic kidney diseases for implementing precision medicine ¹ÚÇýÀÎ(ÇѸ²´ëÇб³)
±³À°½Ã°£ 05-29 Room 1(5F) 15:40~16:10 ÀΰøÁö´É(AI) ½Ã´ëÀÇ ÀÇ·á À±¸® ¹®Á¦ ¾ç±¤¸ð(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-29 Room 1(5F) 16:10~16:40 ÀÇÇÐÀü¹®Á÷¾÷¼º¿¡ ±â¹ÝÇÑ ÀÚÀ²±ÔÁ¦ ¾È´ö¼±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-29 Room 1(5F) 16:40~17:10 ÀÇ·áºÐÀï °¨Á¤ »ç¾È¿¡ ´ëÇÑ ¹ý·üÀû Çؼ® ±è¿¬Èñ(¹ý¹«¹ýÀÎ ÀǼº)
±³À°½Ã°£ 05-29 Room 1(5F) 17:10~17:40 Àΰø½ÅÀå½Ç¿¡¼ÀÇ À±¸®Àû ¹®Á¦ ±è»ó¿í(±¤¸í¼ö³»°ú)
±³À°½Ã°£ 05-29 Room 2(3F) 08:30~10:30 Education on Kidney Transplantation for Patients Initiating Dialysis ÀÌÇÏÁ¤(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 09:00~09:30 Donor Evaluation and Follow Up in Kidney Transplantation ±èÁöÀº(°í·ÁÀǴ뱸·Îº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 09:30~10:00 Recipient Evaluation and Follow Up in Kidney Transplantation ȲÇö¼®(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-29 Room 2(3F) 10:00~10:30 Management of Patients With a Failed Kidney Transplant ±èµµÇü(°³²¼º½Éº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 10:40~11:10 Artery Disease in End Stage Renal Disease Patients: Central / Peripheral ±è»ó¹Î(ÃæºÏ´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 11:10~11:40 Chronic Kidney Disease-Mineral Bone Disorder Management: Fracture Risk Evaluation & Intervention ÀÌÀåÇÑ(ºÐ´çÁ¦»ýº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 11:40~12:10 Blood Pressure in Chronic Kidney Disease/End Stage Renal Disease: 2021 Update ÃÖÇý¹Î(¸íÁö´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 12:10~12:40 Iron Treatment in Chronic Kidney Disease/End Stage Renal Disease Patients ¹ÚÀçÀ±(µ¿±¹´ëÀϻ꺴¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 13:30~13:54 Global Comparison of Nationwide Renal Registry Data ¹ÚÁ¾ÇÏ(¿ï»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 13:54~14:18 °³¿ø°¡ ÀÔÀå¿¡¼ ¹Ù¶óº» µî·Ï»ç¾÷ À±Ã¢¿¬(À±¿µ¼® ³»°úÀÇ¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 14:18~14:42 2022³â Àΰø½ÅÀå½Ç ÀÎÁõÆò°¡ º¸°í ÀÌ¿µ±â(°³²¼º½Éº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 14:42~15:06 ÀûÁ¤¼º Æò°¡ÀÇ °ú°Å, ÇöÀç, ±×¸®°í ¹Ì·¡ ÀÌÁø¿ë(°Ç°º¸Çè½É»çÆò°¡¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 15:06~15:30 Åõ¼®Àü¹®ÀÇÀÇ ÇöÀç¿Í ¹Ì·¡ Ȳ¿ø¹Î(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 05-29 Room 2(3F) 15:40~16:10 Application of Novel Anemia Treatment in Chronic Kidney Disease ±èÁ°æ(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 16:10~16:40 Recent Advances to Control Hyperphosphatemia ȲÁøÈ£(Áß¾ÓÀǴ뺴¿ø)
±³À°½Ã°£ 05-29 Room 2(3F) 16:40~17:10 New Treatment Strategies for Diabetic Nephropathy ¹Ú¿äÇÑ(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 05-29 Room 2(3F) 17:10~17:40 Drug Development of IgA Nephropathy and FSGS(Focal Segmental Glomerulosclerosis) ¹ÚÀçÀ±(µ¿±¹´ëÀϻ꺴¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 08:30~09:00 º¹¸·Åõ¼® ´ã´ç °£È£»çÀÇ ¿ªÇÒ (º¹¸·Åõ¼® ÀçÅðü¸®»ç¾÷) ÀÌ¿µ±â(°³²¼º½Éº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 09:00~09:30 Basic Principles of Peritoneal Dialysis ±èÈ¿Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-29 Room 3(3F) 09:30~10:00 Management of Fluid and Electrolyte Disturbances in Peritoneal Dialysis Patients ±è°æ¹Î(À»ÁöÀǴ뺴¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 10:00~10:30 Management of Complications of Peritoneal Dialysis ±èÇظ®(¼¼Á¾Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 10:40~11:10 Dialysis Water Quality Control ¹Ú»ï¿¤(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-29 Room 3(3F) 11:10~11:40 Nutritonal Support in Hemo Dialysis Patients ±èÇü¿Ï(ÀüºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 11:40~12:10 Management of Chronic Kidney Disease-Mineral Bone Disorder Â÷ÁøÁÖ(°í·Á´ëÇб³¾È»êº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 12:10~12:40 Management of Osteoporosis in Hemo Dialysis Patients ÀÌÇö½Â(Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 13:30~14:00 Arteriovenous Fistula Doppler Ultrasonogram and Access Surveillance ±èÇü¿ì(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 14:00~14:30 Ultrasonogram for Nephrologists ±è⼺(Àü³²´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 14:30~15:00 Intensive Care Nephrology ÀÌÁ¤È¯(¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 15:00~15:30 About Onco-nephrology ÀÌÀç¿í(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-29 Room 3(3F) 15:40~16:10 [2020³â Çùµ¿¿¬±¸°úÁ¦] ±Ù°Å Áß½ÉÀÇ °í·É ¸¸¼ºÄáÆϺ´ ȯÀÚ Áø·áÁöħ: 3³âÂ÷ º¸°í È«À¯¾Æ(´ëÀü°¡Å縯¼º¸ðº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 16:10~16:40 [2020³â Çѱ¹º¸°ÇÀǷῬ±¸¿ø °úÁ¦/2021 Çùµ¿¿¬±¸°úÁ¦] ¸¸¼ºÄáÆϺ´ ȯÀÚ Åõ¼®¹æ¹ý ¼±ÅÃÀ» À§ÇÑ °øµ¿ÀÇ»ç°áÁ¤ ÀÓ»ó½ÃÇè (SDM-ART): 2³âÂ÷ º¸°í ±è¼¼Áß(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 16:40~17:10 [2021³â Çùµ¿¿¬±¸°úÁ¦] ÀΰøÁö´É ±â¹Ý ÀÓ»ó-º´¸® ÅëÇÕ IgA ½ÅÀå¿° ¿¹ÈÄ ¿¹Ãø ¸ðµ¨ °³¹ß ÀÌÇÏÁ¤(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 3(3F) 17:10~17:40 [2021³â Çѱ¹º¸°ÇÀǷῬ±¸¿ø °úÁ¦] A Pragmatic Randomized Clinical Trial: Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients (PRIDE) ±Ç¼øÈ¿(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 08:30~09:00 Impact of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes ±èÇзÉ(¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 09:00~09:30 Updated Guidelines on Blood Pressure Control in Patients With Kidney Diseases ÇѽÂÇõ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 09:30~10:00 Out-Of-Office Blood Pressure Corresponding to 120 mmHg in Intensive Blood Pressure Control ¹Ú¼ºÇÏ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 10:00~10:30 Masked Uncontrolled Hypertension in Chronic Kidney Disease in Intensive Blood Pressure Control °íÀº½Ç(¿©Àǵµ¼º¸ðº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 10:40~11:10 °©»ó¼±ÁúȯÀÇ Áø´Ü°ú Ä¡·áÀÇ ÃÖ½ÅÁö°ß Á¶À±¿µ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 11:10~11:40 Primary Aldosteronism Áø´Ü°ú Ä¡·áÀÇ ÃÖ½ÅÁö°ß ÀÓÁ¤¼ö(¿øÁÖ¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 11:40~12:10 Dyslipidemia Treatment in Chronic Kidney Disease À̼ҿµ(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 12:10~12:40 Osteoporosis Treatment in Chronic Kidney Disease ±è±âÇ¥(ÀÎÇϴ뺴¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 13:30~14:10 Åõ¼® ȯÀÚ¿¡¼ ´Ü¹é ¼·Ãë¿Í ´Ü¹éÁú-¿·® ¿µ¾ç½ÇÁ¶ (PEW) À̼º¿ì(ÀÇÁ¤ºÎÀ»ÁöÀǴ뺴¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 14:10~14:50 Åõ¼® ȯÀÚ¿¡¼ ¿Ã¹Ù¸¥ ´Ü¹é ¼·Ãë ±èÁö¿¬(ÀºÆò¼º¸ðº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 14:50~15:30 ½Ã¿¬: Åõ¼® ȯÀÚ¿¡¼ °Ç°ÇÏ°Ô À߸Դ ½Ä»ç ¸¸µé±â ±è¿ìÁ¤(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 14:50~15:30 ½Ã¿¬: Åõ¼® ȯÀÚ¿¡¼ °Ç°ÇÏ°Ô À߸Դ ½Ä»ç ¸¸µé±â ÃÖÀºÁ¤(ÇѾç´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 08:30~08:40 Effect of Plasminogen Activator Inhibitor-1 (PAI-1) On Phenotype Transition of Human Peritoneal Mesothelial Cells (MCs) ±è´Þ¾Æ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 08:40~08:50 Fasting Blood Glucose Level and All-Cause Mortality in Peritoneal Dialysis Patients ±èÁ¾È£(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 08:50~09:00 Synergy of Selective Inhibitor of PDE-5 and 5-HT2B Receptor: A Potent Anti-fibrotic Strategy for Abrogating Fibrotic Potential of Peritoneal Fibroblasts in PD Patients Saurabh Chaturvedi(GSVM Medical College)
±³À°½Ã°£ 05-29 Room 4(3F) 09:00~09:10 Cross-Talk Between Mesothelial Cells (MCs) And Adipocytes (ACs) As a Trigger for Peritoneal Fibrosis in Peritoneal Dialysis (PD) °ÇöÁ¤(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 09:10~09:20 Combined Impact of Mean and Variability of Non-HDL-Cholesterol on Cardiovascular Risk in Patients Undergoing Hemodialysis ÀÌÇѺñ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 09:20~09:30 Circulating Follistatin-like protein-1 Levels Predicts the Risk of Cardiovascular Events and Death in Hemodialysis Patients ±è´ë±Ô(°µ¿°æÈñ´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 09:30~09:40 Elevated Serum Alkaline Phosphatase Levels and Risk of All-Cause Mortality in Dialysis Patients Md Salman Hussain(Jamia Hamdard)
±³À°½Ã°£ 05-29 Room 4(3F) 09:40~09:50 A Risk Prediction for Early-Peak Mortality in Korean Elderly Hemodialysis Patients: Data From a Multicenter Cohort Study ¹Ú¿ì¿µ(°è¸íÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 05-29 Room 4(3F) 09:50~10:00 Fasting Blood Glucose Level and All-Cause Mortality in Hemodialysis Patients À±¼ö¿µ(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-29 Room 4(3F) 10:00~10:10 Femoral Vein Tunnelled-cuffed Catheters in a Single Tertiary Teaching Hospital: A Five Years Retrospective Study in Malaysia Suek Xuan Pon(University Malaya)
±³À°½Ã°£ 05-29 Room 4(3F) 10:10~10:20 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis ±è´ë±Ô(°µ¿°æÈñ´ëº´¿ø)
±³À°½Ã°£ 05-29 Room 4(3F) 10:20~10:30 Strict Blood Pressure Control Was Associated With Better Survival in Korean Hemodialysis Patients, but Not in Peritoneal Dialysis ÀÌÁÖ°æ(°í·ÁÀǴ뱸·Îº´¿ø)